Analyst Ratings for Editas Medicine (EDIT) [Sells]
EDIT Rating Summary
EDIT Price Target Summary
- Highest: $20.00 (Truist Securities)
- Lowest: $8.00 (RBC Capital)
- Average: $14.00
* Over Last 12-Mos
Overall Rating:
NEUTRAL
Rating Trend:
Avg. $ Target:
$14.00 (+149.6%)
* Over Last 12-Mos
Rating Score: 4.6 / 10
Percentile Rank: 47%
Avg. $ Target:
$14.00 (+149.6%)
* Over Last 12-Mos
Rating Score: 4.6 / 10
Percentile Rank: 47%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 4/16/2021 | Goldman Sachs » Updated 11/17/2022 |
Madhu Kumar | New Coverage | Sell (N/A) |
7.00 (8.00) |
41.53 (5.61) |
-86.49% | Details |
| 1/19/2021 | Morgan Stanley » Updated 11/18/2022 |
Matthew Harrison | Downgrade | Underweight (Equalweight) |
8.00 (10.00) |
75.92 (5.61) |
-92.61% | Details |
 |
||||||||
